On 8 July 2024, Just – Evotec, a subsidiary of Evotec SE, announced that it has expanded its partnership with Sandoz to develop and manufacture multiple biosimilars. The deal was first entered into in May 2023 and is designed to utilise Just – Evotec’s AI driven drug substance development platform and continuous manufacturing technology to expand Sandoz’s pipeline.
In June 2024, Just – Evotec announced that it had been selected by the US Department of Defense to develop an accelerated monoclonal antibody development and manufacturing solution as part of the department’s Manufacturing Optimisation Program.